EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

Trial Profile

EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2009

At a glance

  • Drugs Atorvastatin (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Merck Serono; Pfizer
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top